Ad
related to: new drug to stop pah post hours early morning work
Search results
Results from the WOW.Com Content Network
Selexipag, sold under the brand name Uptravi, is a medication developed by Actelion for the treatment of pulmonary arterial hypertension (PAH). [3] [4] Selexipag and its active metabolite, ACT-333679 (or MRE-269, the free carboxylic acid), are agonists of the prostacyclin receptor, which leads to vasodilation in the pulmonary circulation. [5]
Merck said its drug met the main goal of significantly reducing the time to disease worsening, lung transplantation or death in a late-stage study of 172 patients with advanced stages of the ...
The new company Idorsia was created from former Actelion drug discovery operations and early-stage clinical development assets and listed in June 2017 on the SIX Swiss Exchange. [10] In 2018, Johnson & Johnson announced they would discontinue the development of one of the phase III drugs it acquired during its purchase of Actelion. [2]
Macitentan, sold under the brand name Opsumit, is an endothelin receptor antagonist developed by Actelion and approved for the treatment of pulmonary arterial hypertension (PAH). [5] Macitentan is a dual endothelin receptor antagonist, meaning that it acts as an antagonist of two endothelin (ET) receptor subtypes, ET A and ET B . [ 5 ]
Those living with PAH should work closely with their healthcare team to manage their disease. Support can be found by calling the American Lung Association HelpLine at 1-800-586-4872 and pressing 2.
A host of newly approved drugs for pulmonary arterial hypertension, or PAH, means 2014 will be a battleground for market share in the multibillion-dollar indication. Among those competing will be ...
Sitaxentan is a small molecule that blocks the action of endothelin (ET) on the endothelin-A (ET A) receptor selectively (by a factor of 6000 compared with the ET B). [3] It is a sulfonamide class endothelin receptor antagonist (ERA) and is undergoing Food and Drug Administration (FDA) review for treating pulmonary hypertension.
With new therapies, survival rates are increasing. For 2,635 patients enrolled in The Registry to Evaluate Early and Long-term Pulmonary Arterial Hypertension Disease Management (REVEAL Registry) from March 2006 to December 2009, 1-, 3-, 5-, and 7-year survival rates were 85%, 68%, 57%, and 49%, respectively.
Ad
related to: new drug to stop pah post hours early morning work